Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
BULLFROG AI Aktie jetzt für 0€ handeln | |||||
14:38 | RedChip Companies, Inc.: Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 185 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small... ► Artikel lesen | |
20.06. | BullFrog AI Holdings, Inc.: BullFrog AI's Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar | 3 | GlobeNewswire (USA) | ||
12.06. | BullFrog AI Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.06. | BullFrog AI Holdings, Inc.: BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks to Global Biopharma Clients | 2 | GlobeNewswire (USA) | ||
13.05. | BullFrog AI Holdings, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
28.04. | BullFrog AI Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
11.04. | RedChip Companies, Inc.: Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 315 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / April 11, 2025 / RedChip Companies will air interviews with Bullfrog AI Holdings, Inc. (Nasdaq:BFRG) and Connect Biopharma Holdings Limited (Nasdaq:CNTB) and on... ► Artikel lesen | |
14.03. | BullFrog AI Holdings, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
19.02. | Bullfrog AI Holdings, Inc. (BFRG) to Discuss Breakthrough Psychiatric Research in Fireside Chat on March 5 | 5 | Insider Monkey | ||
27.12.24 | BullFrog AI Holdings, Inc.: BullFrog AI Issues Letter to Stockholders | 227 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial... ► Artikel lesen | |
17.12.24 | BullFrog AI Holdings, Inc.: BullFrog AI Announces Appointment of Chief Financial Officer | 227 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BB BIOTECH | 35,250 | +0,43 % | Zwischen Aufbruch und Wandel: Biotech im Check: Wo liegen die Chancen? - BB Biotech: Diversifizierung innerhalb einer Aktie | Steht die Biotech-Branche vor einem strukturellen Wandel? Enormes Innovationspotenzial und gute Voraussetzungen für M&A-Aktivitäten könnten Schwung in den Sektor bringen. Wie geht es eigentlich der... ► Artikel lesen | |
QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
NOVAVAX | 6,025 | 0,00 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
STRYKER | 334,90 | -0,15 % | Kurs von Stryker fällt ab (334,4293 €) | Im US-amerikanischen Wertpapierhandel liegt die Aktie von Stryker gegenwärtig im Minus. Der jüngste Kurs betrug 387,52 US-Dollar. Die Aktie von Stryker verzeichnet aktuell einen Kursrückgang von 0,86... ► Artikel lesen | |
ILLUMINA | 82,73 | -2,05 % | Illumina Stock: What Went Wrong And Why It's Best To Stay Away | ||
CRISPR THERAPEUTICS | 56,00 | +17,65 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Aktie kommt in Fahrt - jetzt noch kaufen? | Die Aktie des AKTIONÄR-Depotwerts CRISPR Therapeutics hat sich in den vergangenen Wochen enorm stark entwickelt. Zuletzt hat sich die Aufwärtsbewegung sogar noch einmal beschleunigt. Seit dem Tief Anfang... ► Artikel lesen | |
AAP IMPLANTATE | 1,990 | +1,53 % | EQS-News: aap Implantate AG schließt das Geschäftsjahr 2024 erfolgreich ab - positive Entwicklungen trotz herausforderndem Umfeld | EQS-News: aap Implantate AG
/ Schlagwort(e): Jahresbericht
aap Implantate AG schließt das Geschäftsjahr 2024 erfolgreich ab - positive Entwicklungen trotz herausforderndem Umfeld... ► Artikel lesen | |
OCUGEN | 0,860 | -1,24 % | Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,439 | +4,80 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 10,295 | +0,93 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
EDITAS MEDICINE | 2,360 | +0,47 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,429 | +5,93 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,316 | -2,53 % | RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 | ||
TEMPUS AI | 52,50 | 0,00 % | Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer |